BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND NTRK1, ENSG00000198400, 4914, P04629, TRK1, MTC, DKFZp781I14186, p140-TrkA, TRKA, TRK AND Treatment
45 results:

  • 1. Estimating the Prognostic Value of the Ntrk Fusion Biomarker for Comparative Effectiveness Research in The Netherlands.
    Santi I; Vellekoop H; M Versteegh M; A Huygens S; Dinjens WNM; Mölken MR
    Mol Diagn Ther; 2024 May; 28(3):319-328. PubMed ID: 38616205
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer.
    Shitara K; Muro K; Watanabe J; Yamazaki K; Ohori H; Shiozawa M; Takashima A; Yokota M; Makiyama A; Akazawa N; Ojima H; Yuasa Y; Miwa K; Yasui H; Oki E; Sato T; Naitoh T; Komatsu Y; Kato T; Mori I; Yamanaka K; Hihara M; Soeda J; Misumi T; Yamamoto K; Yamashita R; Akagi K; Ochiai A; Uetake H; Tsuchihara K; Yoshino T
    Nat Med; 2024 Mar; 30(3):730-739. PubMed ID: 38347302
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer.
    Taşçı EŞ; Oyan B; Sönmez Ö; Mutlu AU; Atcı MM; Sakin A; Öner İ; Çınkır HY; Eryılmaz MK; Çağlayan D; Balçık OY; Paksoy N; Karabulut S; Salim DK; Bilir C; Özen M; Özçelik M; Arıcan A; Akagündüz B; İnal A; Aydın D; Özer L; Gülmez A; Turhal NS; Esen SA; Algın E; Akbaş S; İriağaç Y; Şakalar T; Ünal Ç; Er Ö; Seçmeler Ş; Bozkurt M
    BMC Cancer; 2024 Jan; 24(1):16. PubMed ID: 38166764
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Ntrk fusions in solid tumours: what every pathologist needs to know.
    Nguyen MA; Colebatch AJ; Van Beek D; Tierney G; Gupta R; Cooper WA
    Pathology; 2023 Aug; 55(5):596-609. PubMed ID: 37330338
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Analysis of surgical outcomes of laparoscopic versus open surgery for locally advanced mid-transverse colon cancer.
    Iguchi K; Numata M; Shiozawa M; Kazama K; Sawazaki S; Katayama Y; Numata K; Higuchi A; Godai T; Sugano N; Mushiake H; Rino Y
    Langenbecks Arch Surg; 2023 Jun; 408(1):222. PubMed ID: 37266706
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. China special issue on gastrointestinal tumors-Ntrk fusion in a large real-world population and clinical utility of circulating tumor DNA genotyping to guide trk inhibitor treatment.
    Qi C; Zhou T; Bai Y; Chen H; Yuan J; Zhao F; Liu C; Ma M; Bei T; Chen S; Zhao X; Chen C; Shen L
    Int J Cancer; 2023 Dec; 153(11):1916-1927. PubMed ID: 36946696
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Analysis Of Common Somatic Mutations In colorectal Carcinoma And Associated Dysregulated Pathwaysarts.
    Hassan S; Khatoon A; Bukhari U; Mirza T
    J Ayub Med Coll Abbottabad; 2023; 35(1):137-143. PubMed ID: 36849394
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Genomic and transcriptomic analysis of MSI-H colorectal cancer patients with targetable alterations identifies clinical implications for immunotherapy.
    Hua H; He W; Chen N; He Y; Wu G; Ye F; Zhou X; Li Y; Ding Y; Zhong W; Teng L; Jiang W; Sheng Q
    Front Immunol; 2022; 13():974793. PubMed ID: 36700211
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. A reciprocal feedback between colon cancer cells and Schwann cells promotes the proliferation and metastasis of colon cancer.
    Han S; Wang D; Huang Y; Zeng Z; Xu P; Xiong H; Ke Z; Zhang Y; Hu Y; Wang F; Wang J; Zhao Y; Zhuo W; Zhao G
    J Exp Clin Cancer Res; 2022 Dec; 41(1):348. PubMed ID: 36522730
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. treatment Patterns of Real-World Patients with trk Fusion cancer Treated by US Community Oncologists.
    Klink AJ; Kavati A; Gassama A; Kozlek T; Gajra A; Antoine R
    Target Oncol; 2022 Sep; 17(5):549-561. PubMed ID: 36089643
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Timing of Ntrk Gene Fusion Testing and treatment Modifications Following trk Fusion Status Among US Oncologists Treating trk Fusion cancer.
    Klink AJ; Kavati A; Gassama AT; Kozlek T; Gajra A; Antoine R
    Target Oncol; 2022 May; 17(3):321-328. PubMed ID: 35716252
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Ntrk fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability.
    Wang H; Li ZW; Ou Q; Wu X; Nagasaka M; Shao Y; Ou SI; Yang Y
    Cancer Med; 2022 Jul; 11(13):2541-2549. PubMed ID: 35506567
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. The potential long-term comparative effectiveness of larotrectinib vs standard of care for treatment of metastatic trk fusion thyroid cancer, colorectal cancer, and soft tissue sarcoma.
    Suh K; Carlson JJ; Xia F; Williamson T; Sullivan SD
    J Manag Care Spec Pharm; 2022 Jun; 28(6):622-630. PubMed ID: 35362337
    [No Abstract]    [Full Text] [Related]  

  • 14. Entrectinib Induces Apoptosis and Inhibits the Epithelial-Mesenchymal Transition in Gastric cancer with Ntrk Overexpression.
    Sohn SH; Sul HJ; Kim BJ; Kim HS; Zang DY
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008821
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Ntrk fusions in colorectal cancer: clinical meaning and future perspective.
    Ratti M; Grizzi G; Passalacqua R; Lampis A; Cereatti F; Grassia R; Hahne JC
    Expert Opin Ther Targets; 2021 Aug; 25(8):677-683. PubMed ID: 34488530
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Patient-reported outcomes from STARtrk-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and Ntrk fusion-positive solid tumours.
    Paz-Ares L; Barlesi F; Siena S; Ahn MJ; Drilon A; Conley A; Rolfo C; Wolf J; Seto T; Doebele R; Kapre A; Chen D; McCallum S; Osborne S; Demetri G
    ESMO Open; 2021 Jun; 6(3):100113. PubMed ID: 33930659
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. trkB/C-induced HOXC6 activation enhances the ADAM8-mediated metastasis of chemoresistant colon cancer cells.
    Park GB; Choi S; Yoon YS; Kim D
    Mol Med Rep; 2021 Jun; 23(6):. PubMed ID: 33846772
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (trk) inhibitors: Design, synthesis, and biological evaluation.
    Yan W; Zhang L; Lv F; Moccia M; Carlomagno F; Landry C; Santoro M; Gosselet F; Frett B; Li HY
    Eur J Med Chem; 2021 Apr; 216():113265. PubMed ID: 33652352
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Detection of tumor-derived cell-free DNA from colorectal cancer peritoneal metastases in plasma and peritoneal fluid.
    Van't Erve I; Rovers KP; Constantinides A; Bolhuis K; Wassenaar EC; Lurvink RJ; Huysentruyt CJ; Snaebjornsson P; Boerma D; van den Broek D; Buffart TE; Lahaye MJ; Aalbers AG; Kok NF; Meijer GA; Punt CJ; Kranenburg O; de Hingh IH; Fijneman RJ
    J Pathol Clin Res; 2021 May; 7(3):203-208. PubMed ID: 33635598
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Canadian Consensus for Biomarker Testing and treatment of trk Fusion cancer in Adults.
    Bebb DG; Banerji S; Blais N; Desmeules P; Gill S; Grin A; Feilotter H; Hansen AR; Hyrcza M; Krzyzanowska M; Melosky B; Noujaim J; Purgina B; Ruether D; Simmons CE; Soulieres D; Torlakovic EE; Tsao MS
    Curr Oncol; 2021 Jan; 28(1):523-548. PubMed ID: 33467570
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 3.